Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression

He,Suqin; Zhang,Chaohua; Shafi,Ayesha  A.; Sequeira,Manuel; Acquaviva,Jaime; Friedland,Julie   C.; Sang,Jim; Smith,Donald  L.; Weigel,Nancy L.; Wada,Yumiko; Proia,David  A.

doi:10.3892/ijo.2012.1698

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression

Authors:
- Suqin He
- Chaohua Zhang
- Ayesha A. Shafi
- Manuel Sequeira
- Jaime Acquaviva
- Julie C. Friedland
- Jim Sang
- Donald L. Smith
- Nancy L. Weigel
- Yumiko Wada
- David A. Proia
View Affiliations

Affiliations: Synta Pharmaceuticals Corp., Lexington, MA 02421, USA, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
Published online on: November 14, 2012 https://doi.org/10.3892/ijo.2012.1698
Pages: 35-43
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Androgen ablation therapy represents the first line of therapeutic intervention in men with advanced or recurrent prostate tumors. However, the incomplete efficacy and lack of durable response to this clinical strategy highlights an urgent need for alternative treatment options to improve patient outcomes. Targeting the molecular chaperone heat shock protein 90 (Hsp90) represents a potential avenue for therapeutic intervention as its inhibition results in the coordinate blockade of multiple oncogenic signaling pathways in cancer cells. Moreover, Hsp90 is essential for the stability and function of numerous client proteins, a number of which have been causally implicated in the pathogenesis of prostate cancer, including the androgen receptor (AR). Here, we examined the preclinical activity of ganetespib, a small molecule inhibitor of Hsp90, in a panel of prostate cancer cell lines. Ganetespib potently decreased viability in all lines, irrespective of their androgen sensitivity or receptor status, and more effectively than the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG). Interestingly, while ganetespib exposure decreased AR expression and activation, the constitutively active V7 truncated isoform of the receptor was unaffected by Hsp90 inhibition. Mechanistically, ganetespib exerted concomitant effects on mitogenic and survival pathways, as well as direct modulation of cell cycle regulators, to induce growth arrest and apoptosis. Further, ganetespib displayed robust antitumor efficacy in both AR-negative and positive xenografts, including those derived from the 22Rv1 prostate cancer cell line that co-expresses full-length and variant receptors. Together these data suggest that further investigation of ganetespib as a new therapeutic treatment for prostate cancer patients is warranted.

View Figures

View References

1.	Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2.	Balk SP and Knudsen KE: AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 6:e0012008.PubMed/NCBI
3.	Chen Y, Sawyers CL and Scher HI: Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 8:440–448. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Scher HI, Buchanan G, Gerald W, et al: Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 11:459–476. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Lonergan PE and Tindall DJ: Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 10:202011. View Article : Google Scholar : PubMed/NCBI
6.	Yap TA, Zivi A, Omlin A and De Bono JS: The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol. 8:597–610. 2011. View Article : Google Scholar : PubMed/NCBI
7.	Osanto S and van Poppel H: Emerging novel therapies for advanced prostate cancer. Ther Adv Urol. 4:3–12. 2012. View Article : Google Scholar
8.	Attard G, Cooper CS and De Bono JS: Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell. 16:458–462. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Hahn JS: The Hsp90 chaperone machinery: from structure to drug development. BMB Rep. 42:623–630. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Whitesell L and Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Saporita AJ, Ai J and Wang Z: The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate. 67:509–520. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Trepel J, Mollapour M, Giaccone G, et al: Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 10:537–549. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Vanaja DK, Mitchell SH, Toft DO, et al: Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones. 7:55–64. 2002. View Article : Google Scholar : PubMed/NCBI
14.	Pratt WB and Toft DO: Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 18:306–360. 1997.PubMed/NCBI
15.	Banerji U: Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res. 15:9–14. 2009. View Article : Google Scholar : PubMed/NCBI
16.	Neckers L: Heat shock protein 90: the cancer chaperone. J Biosci. 32:517–530. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Xu W and Neckers L: Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res. 13:1625–1629. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Li Y, Zhang T, Schwartz SJ and Sun D: New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat. 12:17–27. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Taldone T, Gozman A, Maharaj R, et al: Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol. 8:370–374. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Eskew JD, Sadikot T, Morales P, et al: Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer. 11:4682011. View Article : Google Scholar : PubMed/NCBI
21.	Lamoureux F, Thomas C, Yin MJ, et al: A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res. 17:2301–2313. 2011. View Article : Google Scholar
22.	O’Malley KJ, Langmann G, Ai J, et al: Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance. Prostate. 72:1117–1123. 2011.PubMed/NCBI
23.	Solit DB, Zheng FF, Drobnjak M, et al: 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 8:986–993. 2002.PubMed/NCBI
24.	Heath EI, Hillman DW, Vaishampayan U, et al: A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 14:7940–7946. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Oh WK, Galsky MD, Stadler WM, et al: Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydro-chloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 78:626–630. 2011. View Article : Google Scholar : PubMed/NCBI
26.	Ying W, Du Z, Sun L, et al: Ganetespib, a unique triazolone-containing hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther. 11:475–484. 2012. View Article : Google Scholar : PubMed/NCBI
27.	Nazareth LV, Stenoien DL, Bingman WE, et al: A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1). Mol Endocrinol. 13:2065–2075. 1999. View Article : Google Scholar
28.	Agoulnik IU, Vaid A, Nakka M, et al: Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 66:10594–10602. 2006. View Article : Google Scholar
29.	Nazareth LV and Weigel NL: Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem. 271:19900–19907. 1996. View Article : Google Scholar : PubMed/NCBI
30.	Agoulnik IU, Krause WC, Bingman WE, et al: Repressors of androgen and progesterone receptor action. J Biol Chem. 278:31136–31148. 2003. View Article : Google Scholar : PubMed/NCBI
31.	Proia DA, Foley KP, Korbut T, et al: Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One. 6:e185522011. View Article : Google Scholar : PubMed/NCBI
32.	Dehm SM, Schmidt LJ, Heemers HV, et al: Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68:5469–5477. 2008. View Article : Google Scholar : PubMed/NCBI
33.	Hu R, Dunn TA, Wei S, et al: Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69:16–22. 2009. View Article : Google Scholar : PubMed/NCBI
34.	Li Y, Alsagabi M, Fan D, et al: Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res. 71:2108–2117. 2011. View Article : Google Scholar : PubMed/NCBI
35.	Connolly JM and Rose DP: Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate. 19:173–180. 1991. View Article : Google Scholar : PubMed/NCBI
36.	Okamoto M, Lee C and Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res. 57:141–146. 1997.PubMed/NCBI
37.	Fang Z, Zhang T, Dizeyi N, et al: Androgen receptor enhances p27 degradation in prostate cancer cells through rapid and selective TRC2 activation. J Biol Chem. 287:2090–2098. 2011. View Article : Google Scholar : PubMed/NCBI
38.	Huggins C, Stevens RE and Hodges CV: Studies on prostatic cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg. 43:209–228. 1941. View Article : Google Scholar
39.	Sartor O, Michels RM, Massard C, et al: Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist. 16:1487–1497. 2011. View Article : Google Scholar : PubMed/NCBI
40.	Kim YS, Alarcon SV, Lee S, et al: Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem. 9:1479–1492. 2009. View Article : Google Scholar : PubMed/NCBI
41.	Proia DA, Sang J, He S, et al: Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs. View Article : Google Scholar : [Epub ahead of print]. 2012.PubMed/NCBI
42.	Smith DF and Toft DO: Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. Mol Endocrinol. 22:2229–2240. 2008. View Article : Google Scholar : PubMed/NCBI
43.	Monti S, Proietti-Pannunzi L, Sciarra A, et al: The IGF axis in prostate cancer. Curr Pharm Des. 13:719–727. 2007. View Article : Google Scholar : PubMed/NCBI
44.	Ozkan EE: Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol. 344:1–24. 2011. View Article : Google Scholar
45.	Guo Z, Yang X, Sun F, et al: A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69:2305–2313. 2009. View Article : Google Scholar
46.	Hwang M, Moretti L and Lu B: HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr Med Chem. 16:3081–3092. 2009. View Article : Google Scholar : PubMed/NCBI
47.	Solit DB and Chiosis G: Development and application of Hsp90 inhibitors. Drug Discov Today. 13:38–43. 2008. View Article : Google Scholar : PubMed/NCBI
48.	Arlander SJ, Eapen AK, Vroman BT, et al: Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem. 278:52572–52577. 2003. View Article : Google Scholar : PubMed/NCBI
49.	Flatten K, Dai NT, Vroman BT, et al: The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem. 280:14349–14355. 2005. View Article : Google Scholar : PubMed/NCBI
50.	Munster PN, Basso A, Solit D, et al: Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res. 7:2228–2236. 2001.
51.	Lange BM, Bachi A, Wilm M, et al: Hsp90 is a core centrosomal component and is required at different stages of the centrosome cycle in Drosophila and vertebrates. EMBO J. 19:1252–1262. 2000. View Article : Google Scholar : PubMed/NCBI
52.	De Carcer G: Heat shock protein 90 regulates the metaphaseanaphase transition in a polo-like kinase-dependent manner. Cancer Res. 64:5106–5112. 2004.PubMed/NCBI